BCYC
Price
$6.25
Change
-$0.22 (-3.40%)
Updated
Nov 19 closing price
Capitalization
433.9M
103 days until earnings call
Intraday BUY SELL Signals
IMTX
Price
$10.33
Change
+$0.01 (+0.10%)
Updated
Nov 19 closing price
Capitalization
1.25B
125 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs IMTX

Header iconBCYC vs IMTX Comparison
Open Charts BCYC vs IMTXBanner chart's image
Bicycle Therapeutics
Price$6.25
Change-$0.22 (-3.40%)
Volume$380.63K
Capitalization433.9M
Immatics
Price$10.33
Change+$0.01 (+0.10%)
Volume$597.75K
Capitalization1.25B
BCYC vs IMTX Comparison Chart in %
BCYC
Daily Signal:
Gain/Loss:
IMTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCYC vs. IMTX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and IMTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (BCYC: $6.26 vs. IMTX: $10.32)
Brand notoriety: BCYC and IMTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 107% vs. IMTX: 70%
Market capitalization -- BCYC: $433.9M vs. IMTX: $1.25B
BCYC [@Biotechnology] is valued at $433.9M. IMTX’s [@Biotechnology] market capitalization is $1.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileIMTX’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • IMTX’s FA Score: 0 green, 5 red.
According to our system of comparison, IMTX is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while IMTX’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • IMTX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than IMTX.

Price Growth

BCYC (@Biotechnology) experienced а -4.65% price change this week, while IMTX (@Biotechnology) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 03, 2026.

IMTX is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMTX($1.26B) has a higher market cap than BCYC($434M). IMTX YTD gains are higher at: 45.148 vs. BCYC (-55.321). IMTX has higher annual earnings (EBITDA): -58.05M vs. BCYC (-245.86M). BCYC has more cash in the bank: 648M vs. IMTX (478M). BCYC has less debt than IMTX: BCYC (5.74M) vs IMTX (17.1M). IMTX has higher revenues than BCYC: IMTX (130M) vs BCYC (28.3M).
BCYCIMTXBCYC / IMTX
Capitalization434M1.26B35%
EBITDA-245.86M-58.05M424%
Gain YTD-55.32145.148-123%
P/E RatioN/A27.61-
Revenue28.3M130M22%
Total Cash648M478M136%
Total Debt5.74M17.1M34%
FUNDAMENTALS RATINGS
BCYC vs IMTX: Fundamental Ratings
BCYC
IMTX
OUTLOOK RATING
1..100
5972
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9492
PRICE GROWTH RATING
1..100
8637
P/E GROWTH RATING
1..100
10053
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (13) in the null industry is somewhat better than the same rating for IMTX (74). This means that BCYC’s stock grew somewhat faster than IMTX’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as IMTX (100). This means that BCYC’s stock grew similarly to IMTX’s over the last 12 months.

IMTX's SMR Rating (92) in the null industry is in the same range as BCYC (94). This means that IMTX’s stock grew similarly to BCYC’s over the last 12 months.

IMTX's Price Growth Rating (37) in the null industry is somewhat better than the same rating for BCYC (86). This means that IMTX’s stock grew somewhat faster than BCYC’s over the last 12 months.

IMTX's P/E Growth Rating (53) in the null industry is somewhat better than the same rating for BCYC (100). This means that IMTX’s stock grew somewhat faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCIMTX
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signal:
Gain/Loss:
IMTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STVTX10.41N/A
N/A
Virtus Ceredex Large-Cap Value Equity I
KTCCX15.82N/A
N/A
DWS Science and Technology C
GCEUX101.23N/A
N/A
Green Century Equity Institutional
GSAFX27.92N/A
N/A
Goldman Sachs China Equity R6
JHUKX40.39-0.01
-0.02%
JPMorgan Emerging Markets Equity R4

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-3.32%
RPTX - BCYC
50%
Loosely correlated
-3.36%
NRIX - BCYC
43%
Loosely correlated
+13.09%
RGNX - BCYC
43%
Loosely correlated
-2.84%
AUTL - BCYC
42%
Loosely correlated
-1.55%
BHVN - BCYC
42%
Loosely correlated
+0.11%
More

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
N/A
IDYA - IMTX
55%
Loosely correlated
-1.72%
VYGR - IMTX
52%
Loosely correlated
-2.69%
OCUL - IMTX
51%
Loosely correlated
+2.81%
RGNX - IMTX
51%
Loosely correlated
-2.84%
CGON - IMTX
50%
Loosely correlated
+0.16%
More